170 related articles for article (PubMed ID: 25773930)
1. Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.
Deb TB; Zuo AH; Barndt RJ; Sengupta S; Jankovic R; Johnson MD
Breast Cancer Res Treat; 2015 Apr; 150(2):347-61. PubMed ID: 25773930
[TBL] [Abstract][Full Text] [Related]
2. PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression.
Deb TB; Barndt RJ; Zuo AH; Sengupta S; Coticchia CM; Johnson MD
Cell Cycle; 2014; 13(6):961-73. PubMed ID: 24552815
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy-upregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradation.
Deb TB; Coticchia CM; Barndt R; Zuo H; Dickson RB; Johnson MD
Am J Physiol Cell Physiol; 2008 Aug; 295(2):C365-77. PubMed ID: 18562482
[TBL] [Abstract][Full Text] [Related]
4. Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.
Deb TB; Zuo AH; Wang Y; Barndt RJ; Cheema AK; Sengupta S; Coticchia CM; Johnson MD
Am J Physiol Cell Physiol; 2011 May; 300(5):C1139-54. PubMed ID: 21325639
[TBL] [Abstract][Full Text] [Related]
5. Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN.
Aghazadeh S; Yazdanparast R
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1970-1980. PubMed ID: 28499822
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
7. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
Köninki K; Barok M; Tanner M; Staff S; Pitkänen J; Hemmilä P; Ilvesaro J; Isola J
Cancer Lett; 2010 Aug; 294(2):211-9. PubMed ID: 20193978
[TBL] [Abstract][Full Text] [Related]
8. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
9. Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma.
Cho YA; Choi S; Park S; Park CK; Ha SY
Cancer Genomics Proteomics; 2020; 17(6):747-755. PubMed ID: 33099476
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
[TBL] [Abstract][Full Text] [Related]
11. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.
Baker A; Wyatt D; Bocchetta M; Li J; Filipovic A; Green A; Peiffer DS; Fuqua S; Miele L; Albain KS; Osipo C
Oncogene; 2018 Aug; 37(33):4489-4504. PubMed ID: 29743588
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E
J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222
[TBL] [Abstract][Full Text] [Related]
13. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B
Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601
[TBL] [Abstract][Full Text] [Related]
14. Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer.
Kim JW; Kim DK; Min A; Lee KH; Nam HJ; Kim JH; Kim JS; Kim TY; Im SA; Park IA
J Cancer Res Clin Oncol; 2016 Jan; 142(1):157-65. PubMed ID: 26195282
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy.
Ning L; Guo-Chun Z; Sheng-Li A; Xue-Rui L; Kun W; Jian Z; Chong-Yang R; Ling-Zhu W; Hai-Tong L
Tumour Biol; 2016 Apr; 37(4):5445-54. PubMed ID: 26563373
[TBL] [Abstract][Full Text] [Related]
16. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.
Fujita T; Doihara H; Washio K; Kawasaki K; Takabatake D; Takahashi H; Tsukuda K; Ogasawara Y; Shimizu N
Anticancer Drugs; 2006 Apr; 17(4):455-62. PubMed ID: 16550004
[TBL] [Abstract][Full Text] [Related]
18. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.
Fujita T; Doihara H; Kawasaki K; Takabatake D; Takahashi H; Washio K; Tsukuda K; Ogasawara Y; Shimizu N
Br J Cancer; 2006 Jan; 94(2):247-52. PubMed ID: 16404430
[TBL] [Abstract][Full Text] [Related]
19. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
Collins DM; O'Donovan N; McGowan PM; O'Sullivan F; Duffy MJ; Crown J
Ann Oncol; 2012 Jul; 23(7):1788-95. PubMed ID: 22056974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]